AbbVie Inc. (NYSE:ABBV) is among the many high growth mega cap stocks you can buy and hold for the next 3 years. Evan Seigerman, an analyst at BMO Capital, elevated the value goal on AbbVie Inc. (NYSE:ABBV) to $240 from $215 with an ‘Outperform’ score. This potential upside of almost 10% follows the corporate’s announcement that it has resolved litigation with generic drugmakers, permitting for the early market entry of generic Rinvoq.
Many consider that generic competitors market entry gained’t happen till 2037, 4 years after the 2033 expiration of the composition of matter patent. This is not going to solely support AbbVie Inc. (NYSE:ABBV) in surpassing expectations but in addition make it a prime biotech choose. Even as we speak, if we take into account the year-to-date return delivered by the corporate, it outperforms the market by a wholesome 14.31%.
From the EU-US deal on prescribed drugs and enlargement of its neuroscience portfolio by Gilgamesh’s bretisilocin acquisition to an total improved steering, there’s little doubt the corporate is among the many greatest shares to carry for the upcoming years. These positives level to only one factor: AbbVie Inc. (NYSE:ABBV) is onto one thing massive.
AbbVie Inc. (NYSE:ABBV) is an Illinois-based research-focused biopharmaceutical firm that gives medicines and therapies internationally. The core choices of the corporate embody Humira, Skyrizi, Rinvoq, Imbruvica, and Epkinly.
Whereas we acknowledge the potential of ABBV as an funding, we consider sure AI shares supply larger upside potential and carry much less draw back danger. In case you’re searching for a particularly undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring development, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
